September 8, 2024
Headlines

Biopharma

Lario Therapeutics Secures $6M Grant from The Michael J. Fox Foundation for Parkinson’s Research

Editor05 mins

Lario Therapeutics, a pioneering biopharmaceutical firm dedicated to advancing precision medicines for epileptic and neurological disorders, has been awarded a substantial $6 million USD grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). This funding is earmarked to propel Lario’s preclinical research into CaV2.3 calcium channel inhibitors, heralded as a novel approach to…

Read More

CytoReason Raises $80 Million to Expand AI Disease Models and Establish US Hub

Editor04 mins

CytoReason, a trailblazer in computational disease models for biopharma R&D, has secured $80 million in a funding round led by OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific. This substantial investment marks a pivotal moment for CytoReason as it accelerates its mission to revolutionize pharmaceutical decision-making through advanced AI technology. The new funding will propel CytoReason’s…

Read More